Pathology Core

病理学核心

• 批准号: 10024415
• 负责人: Christopher Paul Crum
• 金额: $ 26.13万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-03 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10024415
• 关键词: Address; Animal Model; Antibodies; Archives; Attention; Award; Biological Markers; Biological Models; Biostatistics Core; Blood; Cancer Center; Case Study; Clinical Research; Clinical Trials; Collaborations; Consent; Dana-Farber Cancer Institute; Data; Data Analyses; Deposition; Destinations; Ensure; Experimental Designs; Freezing; Fresh Tissue; Frozen Sections; Generations; Glean; Goals; Grant; Guidelines; Human; Human Resources; Immune response; Immunofluorescence Immunologic; Individual; Institution; Institutional Review Boards; Laboratories; Life; Malignant neoplasm of ovary; Mission; Monitor; Morphology; Normal tissue morphology; Organoids; Outcome; Ovarian; Ovarian Serous Adenocarcinoma; Paraffin Embedding; Participant; Pathologic; Pathologist; Pathology; Patient-Focused Outcomes; Patients; Procedures; Process; Protocols documentation; Quality Control; Research; Research Activity; Research Personnel; Retrieval; Sampling; Schedule; Services; Site; Standardization; Time; Tissue Banks; Tissue Sample; Tissue Stains; Tissues; Triage; Tumor Tissue; Update; Vaccines; Vision; Visual; Woman; Work; Xenograft procedure; design; experience; experimental study; human tissue; innovation; insight; novel therapeutics; operation; quality assurance; repository; treatment response; vaccine trial

PROJECT SUMMARY The Pathology Core is responsible for overseeing the realm of human tissue, which is ultimately the life blood of the translational projects proposed in this DF/HCC Ovarian Spore application. The primary mission of the Pathology Core is to ground the projects in the visual realities of tissue cyto-morphology as the individual project directors explore new therapies and biomarkers of therapeutic response. The first aim of this core is to ensure that the projects are in compliance with IRB-approved protocols. The second aim will be to ensure access to the highest quality tissue. This task is multifaceted and entails close coordination between core investigators and personnel involved in consenting patients, delivering tissues to the Frozen Section room for allocation, and transporting the tissue to the proper destination. In this setting, quality of service pertains to both the condition of the tissue and the precision with which the tissue is analyzed to ensure that the proper cellular components are selected for study. The third aim for this core will be to provide expert histopathologic interpretation when needed and aid in experimental design and execution when tissue is utilized. All of these aims will be executed in the context of each individual project and other cores. In Project 1 the core will be involved in tissue allocation for sequencing, organoid or patient-derived xenograft generation, and paraffin embedding and sectioning. The core will aid in antibody optimization, immunohistochemical staining of tissue sections, and interpretation of results obtained on tissue in the context of multiple clinical trials. In Project 2, involving a vaccine trial, critical tasks will include allocation of fresh tissue for all activities surrounding vaccine generation and organoid generation as well as for generating paraffin embedded sections. The core will help to assess immune response at the tissue level through multi-plex immunofluorescence analysis to help maximize the information that can be gleaned. In Project 3, the core will aid with fresh, frozen, and fixed tissue acquisition and allocation to allow for the varied analyses to be performed in the context of a clinical trial. Moreover, the core investigators must be ever cognizant of maintaining the tissue banks at each site and providing tissue for the Organoid, model organisms, and biomarkers core as well as aiding the biostatistics core in interpretation of immunohistochemical results with respect to patient outcomes. Amidst this panoply of diverse tasks, the core investigators must maintain an organized hierarchy of task assignment and carefully set priorities. This will be achieved by experienced pathologist-investigators who will interact regularly and effectively to integrate the work being done across multiple institutions and develop protocols and procedures with established safeguards of quality assurance. Finally, this integrated Pathology Core will be dynamic, with attention to weaknesses in the data interpretation and consideration of innovative approaches prompted by either necessity or opportunity.

项目概要 病理学核心负责监督人体组织领域，这最终是生命 DF/HCC 卵巢孢子申请中提出的转化项目的血液。主要使命 病理学核心是将项目建立在组织细胞形态学的视觉现实中，作为个体 项目主管探索新疗法和治疗反应的生物标志物。该核心的首要目标是 确保项目符合 IRB 批准的协议。第二个目标是确保 获得最高品质的组织。这项任务是多方面的，需要核心之间的密切协调 研究人员和参与患者同意的人员，将组织运送到冰冻切片室进行 分配，并将组织运输到正确的目的地。在这种情况下，服务质量涉及 组织的状况和组织分析的精度，以确保正确的 选择细胞成分进行研究。该核心的第三个目标是提供组织病理学专家 需要时进行解释，并在使用组织时帮助实验设计和执行。所有这些 目标将在每个单独项目和其他核心的背景下执行。在项目1中，核心是 参与测序的组织分配、类器官或患者来源的异种移植物生成以及石蜡 包埋和切片。核心将有助于抗体优化、组织免疫组织化学染色 切片，以及在多项临床试验的背景下对组织获得的结果的解释。在项目2中， 涉及疫苗试验，关键任务将包括为疫苗相关的所有活动分配新鲜组织 生成和类器官生成以及生成石蜡包埋切片。核心将有助于 通过多重免疫荧光分析评估组织水平的免疫反应，以帮助最大化 可以收集到的信息。在项目 3 中，核心将有助于新鲜、冷冻和固定的组织 采集和分配，以便在临床试验的背景下进行各种分析。 此外，核心研究人员必须始终认识到维护每个地点的组织库和 为类器官、模型生物和生物标志物核心提供组织并帮助生物统计 解释免疫组织化学结果与患者结果相关的核心。在这五花八门之中 任务多样化，核心研究者必须保持任务分配的有组织的层次结构并仔细设置 优先事项。这将由经验丰富的病理学家研究人员来实现，他们将定期互动并 有效整合多个机构正在进行的工作并制定协议和程序 具有既定的质量保证保障措施。最后，这个集成的病理学核心将是动态的， 注意数据解释中的弱点并考虑创新方法 要么是必要性，要么是机会。